[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Innovent Biologics Technology Limited (Shanghai R&D Center)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,64,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100605275","phase-1-a-study-of-ibi3032-in-chinese-healthy-participants-and-participants-with-overweight-or-obesity-100605275",false,"NCT07160400","A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity","A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. Male or female aged 18-65 years (inclusive) at the time of informed consent.\n2. Participants must understand the procedures and methods of this study, be willing to complete the study in strict accordance with the clinical study protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. The investigator suspects that the participant may be allergic to any component of the study drug or GLP-1 receptor agonists, or have used GLP-1 receptor agonists within 3 months prior to screening.\n2. History of diabetes, or HbA1c ≥ 6.5% and fasting blood glucose \\\u003C 3.9 mmol\u002FL or ≥ 7.0 mmol\u002FLat screening.\n3. Presence of any other abnormalities in vital signs and laboratory tests that are clinically significant as judged by the investigator at screening.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.",[28],"Part A: Healthy Part B: Overweight or Obesity","RECRUITING","2026-04-07",{"date":32,"type":33},"2026-04-08","ACTUAL",{"date":35,"type":33},"2025-09-04",{"date":37,"type":22},"2026-09-30",{"name":39,"class":40},"Innovent Biologics Technology Limited (Shanghai R&D Center)","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100624804","phase-3-tigulixostat-ibi128-vs-febuxostat-in-gout-100624804","NCT07414394","Tigulixostat (IBI128) vs Febuxostat in Gout","A Randomized, Double-Blind, Double-Dummy, Multi-Center, Phase III Study Comparing the Efficacy and Safety of Tigulixostat (IBI128) and Febuxostat in Chinese Subjects With Gout","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for the study:\n\n1. Age ≥ 18 years, male or female.\n2. Body mass index (BMI) between 18 and 40 kg\u002Fm².\n3. Diagnosed with gout according to the 2015 ACR\u002FEULAR classification criteria.\n4. Serum uric acid (sUA) at screening:\n\n   ≥ 480 μmol\u002FL for subjects without comorbidities;\n\n   ≥ 420 μmol\u002FL for subjects with at least one concurrent condition (e.g., ≥ 2 gout attacks\u002Fyear, tophi, chronic gouty arthritis, hypertension, diabetes, dyslipidemia, age of onset \\\u003C 40 years).\n5. Voluntarily sign the informed consent form and agree to strictly follow the protocol requirements.\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be excluded from the study:\n\n1. History of allergy or intolerance to any component of febuxostat or Tigulixostat, or previous evidence of poor response to febuxostat treatment (e.g., sUA \\> 420 μmol\u002FL after ≥ 6 weeks of febuxostat ≥ 40 mg).\n2. Acute gout attack within 4 weeks prior to screening or from screening to first dose.\n3. Use of uric acid-lowering drugs (e.g., allopurinol, febuxostat, probenecid, benzbromarone, dotinurad, recombinant uricase; excluding sodium bicarbonate) within 2 weeks before screening.\n4. Hyperuricemia caused by secondary gout (e.g., myeloproliferative disease, tumor, organ transplantation, enzyme deficiency, renal tubular dysfunction, lead poisoning, psoriasis, medications), excluding hyperuricemia due to renal insufficiency.\n5. Use of the following medications or therapies prior to screening or planned during the study:\n\n(1)Prior urate oxidase treatment; (2)Concomitant medications affecting uric acid levels within 4 weeks before screening with dose adjustments (e.g., losartan, calcium channel blockers, diuretics, fenofibrate, atorvastatin, α-glucosidase inhibitors, insulin sensitizers, DPP4 inhibitors, SGLT2 inhibitors, metformin, GLP-1 receptor agonists, pyrazinamide, aspirin); (3)Long-term drugs dependent on xanthine oxidase metabolism (e.g., azathioprine, mercaptopurine); (4)Oral corticosteroids ≥ 10 consecutive days, or intramuscular\u002Fintravenous\u002Fintra-articular corticosteroid injection within 4 weeks before screening; (5)Biologics (e.g., TNF-α inhibitors, IL-1 inhibitors, IL-6 inhibitors) within 12 weeks before screening.\n\n6\\. History or evidence of any of the following diseases:\n\n1. Xanthinuria, Lech-Nyhan syndrome, 5-phosphoribosyl-1-pyrophosphate synthetase superactivity, congenital myogenic hyperuricemia, rhabdomyolysis;\n2. Uncontrolled severe pain not caused by gout;\n3. Cardiovascular events or conditions within 6 months (e.g., acute MI, ACS, unstable angina, CABG, PCI, TIA, cerebrovascular accident, severe arrhythmia, NYHA class III\u002FIV heart failure);\n4. QTcF ≥ 480 ms or history of prolonged QTc interval;\n5. Poorly controlled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) or recent adjustment of antihypertensive drugs;\n6. Poorly controlled diabetes (HbA1c ≥ 9.0%);\n7. Autoimmune or inflammatory diseases requiring systemic immunosuppressive treatment;\n8. Active peptic ulcer or GI bleeding within 1 month;\n9. Diseases affecting drug absorption (e.g., IBS, IBD);\n10. Active hepatitis B, C, HIV, or syphilis infection;\n11. Active or untreated malignancy within 5 years, except specified low-risk cancers;\n12. Thyroid dysfunction requiring treatment. 7. Laboratory abnormalities:\n\n(1)total bilirubin \\> 2×ULN, ALT or AST \\> 3×ULN; (2)eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m². 8. Pregnant or lactating women, or participants unwilling to use effective contraception during the study and for 8 weeks after study end.\n\n9\\. History of alcohol or drug abuse (weekly alcohol \\> 21 units for males, \\> 14 units for females).\n\n10\\. Blood donation or loss ≥ 400 mL within 3 months, or prior blood transfusion.\n\n11\\. Participation in another interventional clinical trial within 3 months or 5 half-lives of prior investigational drug.\n\n12\\. Major surgery within 3 months, incomplete recovery, or planned major surgery during study.\n\n13\\. Presence of mental illness deemed inappropriate for study participation by the investigator.\n\n14\\. Any other condition judged by the investigator to potentially affect study efficacy or safety evaluation.",{"count":50,"type":22},600,[52],"PHASE3","The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \\\u003C 360 μmol\u002FL at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and quality of life over 52 weeks of treatment. Approximately 600 eligible participants will be randomized to receive either Tigulixostat or Febuxostat.",[55],"Gout","2026-03-24",{"date":58,"type":33},"2026-03-25",{"date":60,"type":33},"2026-03-17",{"date":62,"type":22},"2027-10-30",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100618131","early-phase-1-this-is-a-multi-center-study-of-ibi3026-in-participants-with-locally-advanced-unresectable-or-metastatic-solid-tumors-100618131","NCT07327632","This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors","A Multi-Center, Open-Label, Phase 1 Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors","inclusion criteria:\n\n1. Participants must have the ability to understand and sign a written informed consent form for participation in this study, including all assessments and procedures specified in the protocol;\n2. Male or female participants aged ≥18 years;\n3. At least one measurable lesion as defined by RECIST v1.1 within 28 days prior to the first dose of IBI3026;\n4. ECOG performance status of 0-1;\n5. Life expectancy of at least 12 weeks at the start of treatment;\n6. The screening period confirms that bone marrow and organ functions are good.\n7. Male or female participants who are either of non-reproductive potential or agree to use at least one highly effective method of contraception during the study period (starting from screening or 2 weeks prior to first dosing, whichever comes first, and continuing until 6 months after the last dose of study drug);\n8. Not amenable to curative surgical resection or definitive chemoradiotherapy.\n\nExclusion criteria:\n\n1. Prior treatment with IL-12 class cytokines or IL-12 inhibitors;\n2. Participation in any interventional clinical study other than observational (non-interventional) studies, or currently in the follow-up period of an interventional study;\n3. Adverse reactions from prior anti-tumor therapies that have not resolved to Grade 0 or 1, or baseline levels, according to NCI CTCAE v5.0, prior to the first dose of study drug (exceptions include alopecia, fatigue, hyperpigmentation, or other conditions deemed without safety risk by the investigator);\n4. Prior immune checkpoint inhibitor therapy associated with severe adverse reactions sufficient to compromise participant safety;\n5. Known hypersensitivity, allergic reaction, or intolerance to IBI3026 or its excipients (refer to Investigator's Brochure).\n6. Received major surgery (e.g., craniotomy, thoracotomy, or laparotomy, or other surgeries as determined by the investigator) within 4 weeks prior to the first dose of study drug, excluding core biopsy; or anticipated to undergo major surgery during the study period; or presence of serious non-healing wounds, trauma, ulcers, etc.\n7. Known symptomatic central nervous system (CNS) metastases. Participants with asymptomatic CNS metastases (i.e., no neurological syndrome and metastatic lesion diameter ≤1.5 cm) or those with stable disease post-treatment as judged by the investigator may be considered under the following conditions: absence of midbrain, pons, cerebellum, meninges, medulla oblongata, or spinal cord involvement; clinically stable for at least 4 weeks prior to the first dose of study drug (stable on ≤1.5 mg\u002Fday dexamethasone or equivalent corticosteroid and baseline anticonvulsant therapy), with no clinically confirmed new or enlarging CNS lesions.\n8. Tumor invasion into surrounding critical structures (e.g., mediastinal vessels, superior vena cava, trachea, esophagus, etc.) or at risk of gastrointestinal\u002Frespiratory fistula formation.",{"count":72,"type":22},300,[74],"EARLY_PHASE1","This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).",[77],"Solid Tumor","2026-02-02",{"date":80,"type":33},"2026-02-04",{"date":82,"type":33},"2026-01-29",{"date":84,"type":22},"2028-12-31",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":41},"100614149","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-ibi302insubjects-with-namd-100614149","NCT07275840","A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD","An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Have signed an informed consent form before participating in the research.\n2. Male or female individuals aged 50 or above at the time of signing the informed consent form;\n3. Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.\n4. At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).\n\nExclusion Criteria:\n\n1. According to the investigator's judgment, concomitant ocular diseases\u002Fsystemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;\n2. The study eye has uncontrollable glaucoma;\n3. There is an active intraocular or periocular infection or inflammation in either eye;\n4. The non-study eye has severe visual function disorders;\n5. Within 90 days before baseline, the study eye had received anti-VEGF treatment;\n6. Within 90 days before baseline, the study eye had received anti-complement treatment;\n7. At any time before baseline, the study eye had received IBI302 treatment;\n8. Uncontrollable hypertension;\n9. Glycated hemoglobin (HbA1c) \\> 10.0% within 28 days prior to screening;\n10. Other exclusion criteria set by protocol.","50 Years",{"count":95,"type":22},800,[97],"PHASE2","This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.",[100],"Neovascular Age-related Macular Degeneration","2026-01-07",{"date":103,"type":33},"2026-01-08",{"date":105,"type":33},"2025-12-05",{"date":107,"type":22},"2026-08-30",{"name":39,"class":40},""]